seven (24%) reported using only tetrahydrocannabinol (THC)containing products, seven (24%) reported using only nicotinecontaining products, 13 (45%) reported using both, and two (7%) reported using flavored products containing neither THC nor nicotine. A total of 20 (69%) reported using any THCcontaining product; among those with available information on product use, eight of 15 (53%) reported using the product daily, 14 of 19 (74%) reported using products labeled "Dank Vapes," and 10 of 20 (50%) obtained the products from a friend or other acquaintance. The percentage of Indiana EVALI patients who reported using THC-containing products (69%) was lower than that reported by patients in Utah (92%), Illinois and Wisconsin (80%), and nationally (80%) (1-3). Reported concurrent use of THC-containing and nicotine-containing products in Indiana (45%) was also slightly lower than that reported nationally (52%) (1) . Further, nearly one third (31%) of Indiana patients reported using products that did not contain THC. These findings need to be investigated to determine whether Indiana patients might have underreported THC use or whether use of multiple product types might cause EVALI. Results of this investigation of Indiana EVALI patients were consistent with findings from Illinois that frequently using THC-containing products and obtaining these products through personal contacts has been associated with EVALI (4). In addition, the high proportion of reported use of Dank Vape products might be important, because these products are largely counterfeit (4) .
The findings in this report are subject to at least four limitations. First, medical record abstractions were completed for one half of EVALI patients in Indiana, and only one third were interviewed, which might result in selection bias and inaccurate estimates of patient characteristics and product use patterns. Second, preexisting conditions and details of medical care were
Summary
What is already known about this topic?
As of December 4, 2019, 2,291 U.S. persons have been hospitalized with cases of e-cigarette, or vaping, product use-associated lung injury (EVALI). Among those with available data, 80% reported using products containing tetrahydrocannabinol (THC).
What is added by this report?
During August 8-October 28, 2019, 97 patients in Indiana were hospitalized with confirmed or probable cases of EVALI. Interviews were completed for 29 patients; among these, 69% reported using THC-containing products.
What are the implications for public health practice?
The percentage of Indiana EVALI patients reporting THC use was low compared with that reported for all U.S. EVALI patients. This might be due to underreporting of THC use but could also suggest that EVALI is not exclusively associated with THC use. not consistently documented in medical records. Therefore, percentages reported here could be underestimates. Third, because THC-containing products are illegal in Indiana, use of these products might be underreported for fear of legal repercussions or perceived stigma. Finally, only hospitalized cases in Indiana were investigated, potentially leading to bias related to the severity of cases.
The specific cause, or causes, of EVALI has not yet been determined. Vitamin E acetate, frequently used as a thickening agent in THC-containing products, has been detected in bronchoalveolar lavage samples from 29 EVALI patients in 10 states and five EVALI patients in Minnesota (5, 6) . However, it is possible that more than one compound or ingredient could be the cause, and evidence is not yet sufficient to rule out contributions of other toxicants to EVALI. CDC recommends not using e-cigarette, or vaping, products containing THC, especially those obtained from informal sources such as friends, family, or in-person or online dealers (1) . Because the specific cause or causes of lung injury are not yet known, persons should consider refraining from use of all e-cigarette, or vaping, products (1). Youths, young adults, or women who are pregnant should never use e-cigarette, or vaping, products (1).
